Zaandam, the Netherlands, August 29, 2017 - Ahold Delhaize has repurchased 1,444,189 of Ahold Delhaize common shares in the period from August 21, 2017 up to and including August 25, 2017. The shares were repurchased at an average price of €16.46 per share for a total consideration of €23.8 million. These repurchases were made as part of the €1 billion share buyback program announced on December 7, 2016.
The total number of shares repurchased under this program to date is 40,172,740 common shares for a total consideration of €753 million.
Download the share buyback transactions excel sheet for detailed individual transaction information from www.aholddelhaize.com/en/investors/share-information/share-buy-back-programs/


Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Instagram Outage Disrupts Thousands of U.S. Users
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 



